Evidence map›Paper›PMID 40721561›Full record

SynthesisJournal of nephrology2025

Efficacy and safety of TRF-budesonide in IgA nephropathy treatment: a meta-analysis.

Jiayi Li, Hongqin Tai, Bo Yang, Jiayu Xu, Chenchen Zhou, Jing Xu, Cheng Xue, Zhiguo Mao

Abstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Journal of nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jiayi Li *Division of Nephrology, Department of Nephrology, Shanghai Changzheng Hospital, Second Military Medical University (Naval Medical University), 415 Fengyang Road, Shanghai, 200003, China.
Hongqin Tai *Division of Nephrology, Department of Nephrology, Shanghai Changzheng Hospital, Second Military Medical University (Naval Medical University), 415 Fengyang Road, Shanghai, 200003, China.
Bo YangInternal Medicine III (Nephrology), Naval Medical Center of PLA, Naval Medical University, Shanghai, China.
Jiayu Xu *Department of Ultrasound, Zhabei Central Hospital of JingAn District of Shanghai, Shanghai, China.
Chenchen ZhouDivision of Nephrology, Department of Nephrology, Shanghai Changzheng Hospital, Second Military Medical University (Naval Medical University), 415 Fengyang Road, Shanghai, 200003, China.
Jing XuDivision of Nephrology, Department of Nephrology, Shanghai Changzheng Hospital, Second Military Medical University (Naval Medical University), 415 Fengyang Road, Shanghai, 200003, China.
Cheng XueDivision of Nephrology, Department of Nephrology, Shanghai Changzheng Hospital, Second Military Medical University (Naval Medical University), 415 Fengyang Road, Shanghai, 200003, China. chengxia1568@126.com.
Zhiguo MaoDivision of Nephrology, Department of Nephrology, Shanghai Changzheng Hospital, Second Military Medical University (Naval Medical University), 415 Fengyang Road, Shanghai, 200003, China. maozhiguo518@126.com.

Funding

Oriental Talent Plan Outstanding Program 2023, Shanghai Municipal Key Clinical Specialty shslczdzk02503Research Projects of Shanghai Science and Technology Committee 17411972100Shanghai Science and Technology Talent Program 19YF1450300the National Natural Science Foundation of China 81770670the National Natural Science Foundation of China 81873595the National Natural Science Foundation of China 82070705the National Natural Science Foundation of China 82200786
6 · The paper itself

Abstract

backgroundIgA nephropathy (IgAN) is a common glomerular disease characterized by IgA glomerular, typically mensangial deposition, often leading to progressive kidney damage.

methodsThis meta-analysis assessed the efficacy and safety of TRF-budesonide in IgAN patients, using data from four randomized controlled trials involving 774 participants. We calculated the mean differences in estimated glomerular filtration rate (eGFR) and urine-to-protein-creatinine ratio (UPCR) compared to baseline, with 95% confidence intervals (CIs) after 9 months of treatment and at the end of the follow-up period, while also summarizing adverse events.

resultsTRF-budesonide significantly reduced UPCR (weighted mean difference [WMD] = - 0.39 g/g, 95% CI - 0.51, - 0.26, p < 0.00001, I

conclusionsTRF-budesonide demonstrated efficacy and a tolerable safety profile in the treatment of IgAN.

Indexed as

Glomerulonephritis, IGAKidneyCreatinineFemaleGlomerular Filtration RateHumansMaleProteinuriaRandomized Controlled Trials as TopicTreatment OutcomeCreatinineIgA nephropathyMeta-analysisTreatmentTRF-budesonide

Identifiers

PMID40721561

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.